Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
40.64
-2.46 (-5.71%)
Mar 13, 2025, 4:00 PM EST - Market closed
Guardant Health Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for Guardant Health stock have an average target of 48.4, with a low estimate of 32 and a high estimate of 60. The average target predicts an increase of 19.09% from the current stock price of 40.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Guardant Health stock from 20 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 | 11 | 11 |
| Buy | 6 | 6 | 6 | 5 | 8 | 9 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 15 | 19 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $42 → $52 | Buy | Maintains | $42 → $52 | +27.95% | Mar 6, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $34 → $50 | Buy | Maintains | $34 → $50 | +23.03% | Feb 26, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $56 | Strong Buy | Reiterates | $56 | +37.80% | Feb 24, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $47 → $52 | Buy | Maintains | $47 → $52 | +27.95% | Feb 24, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $42 → $60 | Strong Buy | Maintains | $42 → $60 | +47.64% | Feb 24, 2025 |
Financial Forecast
Revenue This Year
880.27M
from 739.02M
Increased by 19.11%
Revenue Next Year
1.07B
from 880.27M
Increased by 21.44%
EPS This Year
-2.92
from -3.56
EPS Next Year
-2.37
from -2.92
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 902.3M | 1.1B | 1.5B | ||
| Avg | 880.3M | 1.1B | 1.3B | ||
| Low | 825.6M | 955.5M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.1% | 29.5% | 43.0% | ||
| Avg | 19.1% | 21.4% | 23.3% | ||
| Low | 11.7% | 8.5% | 1.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.63 | -0.92 | 0.63 | ||
| Avg | -2.92 | -2.37 | -0.35 | ||
| Low | -4.00 | -4.40 | -1.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.